The widespread increase of colorectal cancer cases is driving growth of the U.S. colorectal cancer screening market

The colorectal cancer screening market in the U.S. includes various diagnostic tests used to detect the presence of colorectal cancer or its precursors. Some of the major product types available in this market are fecal occult blood tests (FOBT), biomarkers tests, flexible sigmoidoscopy, and colonoscopy. Colonoscopy provides direct visualization of the colon and rectum and is considered the gold standard for colorectal cancer screening. It allows detection of polyps or cancers and removal of pre-cancerous polyps in the same procedure.
U.S. colorectal cancer screening market size was valued at US$ 5.95 Bn in 2023 and is expected to reach US$ 10.62 Bn by 2031, grow at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.

Key Takeaways

Key players operating in the U.S. colorectal cancer screening market are Abbott Laboratories, Clinical Genomics Technologies, Epigenomics Inc., Roche Diagnostics, and Exact Science. Abbott Laboratories and Roche Diagnostics hold a significant share of this market.

U.S. colorectal cancer screening market Demand for colorectal cancer screening is growing significantly owing to the rising incidence of colorectal cancer cases in the U.S. population. According to the American Cancer Society, colorectal cancer is the third leading cause of cancer-related deaths in the country. Increasing awareness about the importance of early detection is further boosting the uptake of colorectal cancer screening tests.

U.S. Colorectal Cancer Screening Market
https://www.coherentmi.com/ind....ustry-reports/us-col